Gwilym Thompson

Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia

Keith Tolley, Catherine Goad, Yunni Yi et al. · The European Journal of Health Economics · 2012 · 91 citations

Pharmacy, Oncology, Cost-utility Analysis +14

Fluorescence-guided transurethral resection of bladder cancer using hexaminolevulinate: analysis of health economic impact in Sweden

Per‐Uno Malmström, Hans Hedelin, Yngvil Kloster Thomas et al. · Scandinavian Journal of Urology and Nephrology · 2009 · 37 citations

Medicine, Surgery, Urology +17

CheckMate 459: Health-related quality of life (HRQoL) in a randomized, multicenter phase III study of nivolumab (NIVO) versus sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC).

Julien Edeline, Thomas Yau, Joong‐Won Park et al. · Journal of Clinical Oncology · 2020 · 32 citations

Medicine, Oncology, Pharmacotherapy +17

Treatment practices in adults with chronic immune thrombocytopenia – a European perspective

Francesco Rodeghiero, Juan Besalduch, Marc Michel et al. · European Journal Of Haematology · 2009 · 24 citations

Medicine, Hematology, Internal Medicine +14

Estimating outcomes and cost effectiveness using a single-arm clinical trial: ofatumumab for double-refractory chronic lymphocytic leukemia

Anthony J. Hatswell, Gwilym Thompson, Penny Maroudas et al. · Cost Effectiveness and Resource Allocation · 2017 · 16 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +17